TAZVERIK Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tazverik, and when can generic versions of Tazverik launch?
Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-four patents protecting this drug.
This drug has three hundred and fifty-four patent family members in thirty-nine countries.
The generic ingredient in TAZVERIK is tazemetostat hydrobromide. One supplier is listed for this compound. Additional details are available on the tazemetostat hydrobromide profile page.
DrugPatentWatch® Generic Entry Outlook for Tazverik
Tazverik will be eligible for patent challenges on January 23, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 19, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TAZVERIK
| International Patents: | 354 |
| US Patents: | 24 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 72 |
| Clinical Trials: | 13 |
| Patent Applications: | 346 |
| Drug Prices: | Drug price information for TAZVERIK |
| What excipients (inactive ingredients) are in TAZVERIK? | TAZVERIK excipients list |
| DailyMed Link: | TAZVERIK at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAZVERIK
Generic Entry Date for TAZVERIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TAZVERIK
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Jacob Soumerai, MD | Phase 1/Phase 2 |
| MEI Pharma, Inc. | Phase 1/Phase 2 |
| Weill Medical College of Cornell University | Phase 1 |
Pharmacology for TAZVERIK
Anatomical Therapeutic Chemical (ATC) Classes for TAZVERIK
US Patents and Regulatory Information for TAZVERIK
TAZVERIK is protected by thirty-eight US patents and five FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAZVERIK is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TAZVERIK
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING FOLLICULAR LYMPHOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING LYMPHOMA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Methods of treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Method for treating cancer
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
FDA Regulatory Exclusivity protecting TAZVERIK
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
Exclusivity Expiration: ⤷ Try a Trial
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷ Try a Trial
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷ Try a Trial
INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TAZVERIK
When does loss-of-exclusivity occur for TAZVERIK?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15350108
Estimated Expiration: ⤷ Try a Trial
Patent: 21204706
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2017010166
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 67664
Estimated Expiration: ⤷ Try a Trial
China
Patent: 7249591
Estimated Expiration: ⤷ Try a Trial
Patent: 6650500
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 20916
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 1791095
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 20916
Estimated Expiration: ⤷ Try a Trial
Finland
Patent: 20916
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 2182
Estimated Expiration: ⤷ Try a Trial
Patent: 6080
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 29684
Estimated Expiration: ⤷ Try a Trial
Patent: 17537899
Estimated Expiration: ⤷ Try a Trial
Patent: 21073241
Estimated Expiration: ⤷ Try a Trial
Patent: 23062189
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 20916
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 17006089
Estimated Expiration: ⤷ Try a Trial
Patent: 21006734
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 20916
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201703806X
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 2338802
Estimated Expiration: ⤷ Try a Trial
Patent: 170103768
Estimated Expiration: ⤷ Try a Trial
Patent: 210156840
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 47819
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TAZVERIK around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 2908823 | ⤷ Try a Trial | |
| Canada | 2888021 | COMPOSES DE BENZENE SUBSTITUE (SUBSTITUTED BENZENE COMPOUNDS) | ⤷ Try a Trial |
| Russian Federation | 2017132054 | АРИЛ- ИЛИ ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ БЕНЗОЛЬНЫЕ СОЕДИНЕНИЯ | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
